2012 Fiscal Year Final Research Report
Development of novel therapy for skin inflammatory diseases targeting PKCeta
| Project/Area Number |
22590105
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
OHBA Motoi 昭和大学, 腫瘍分子生物学研究所, 講師 (70297018)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | ゲノム創薬 |
|---|
| Research Abstract |
My goal is to develop a novel therapeutic method for severe skin inflammatory diseases including atopic dermatitis(AD) targeting PKCη. Inhibition of PKCη activity by using the dominant negative type of PKCη improved the symptom such as erosiom and fissure on the back skin of AD model mice. Moreover, novel siRNA sequences for PKCη, which significantly repress the PKCη gene expression, were found.Furthermore, Stimulus by wound and reactive oxygen species existed as an upstream signal of PKCη, suggesting that these signals enhance AD symptom via the increase of PKCη activity.
|
-
[Journal Article] Activation of PAR-2 stimulates sVEGFR-1 release via EGF receptortransactivation in endothelial cells2010
Author(s)
Bahjat Al-Ani, Peter W. Hewett, Melissa J. Cudmore, Takeshi Fujisawa, Mahmoud, Saifeddine, Hannah Williams, Wenda Ramma, Samir Sissaoui, Padma-Sheela, Jayaraman, Motoi Ohba, Shakil Ahmad, Morley D.Hollenberg and Asif Ahmed.
-
Journal Title
Hypertention
Volume: 55(3)
Pages: 689-97
DOI
Peer Reviewed
-
-
-
-
-
-
-
